{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:16:40Z","timestamp":1789906600176,"version":"4.0.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"abstract":"<jats:p>\n                    Generalized myasthenia gravis (gMG) is a chronic autoimmune condition characterized by muscle weakness. If frontline treatments inadequately manage symptoms, patients may require use of glucocorticoids (GC); however, long-term use of GCs is associated with toxicities. Few studies have examined the incidence of GC-related toxicities and economic burden among patients with gMG. This study aims to describe GC toxicities, healthcare resource utilization, and costs among US adults with gMG, stratified by level of GC use. Adults with gMG were identified using IQVIA PharMetrics\n                    <jats:sup>\u00ae<\/jats:sup>\n                    Plus data and classified into 2 mutually exclusive cohorts based on GC use during the most recent 12 months of health plan enrollment (study period): \u201cno GC use\u201d (no GC fills) or \u201cany GC use\u201d (\u22651 GC fill). The \u201cany GC use\u201d cohort was stratified into \u201c\u22655\u2009mg\/d\u201d (mean prednisone equivalent daily dose\u2005\u22655\u2009mg) and \u201c\u226510\u2009mg\/d\u201d (mean prednisone equivalent daily dose\u2005\u226510\u2009mg) subgroups. GC use, incident GC toxicities, and all-cause healthcare resource utilization and costs were described during the study period for each cohort and subgroup. Among 8833 patients with gMG, 5076 (57.5%) had no GC use and 3757 (42.5%) had any GC use (\u22655\u2009mg\/d: 1537 [40.9%]; \u226510\u2009mg\/d: 860 [22.9%]). Use of nonsteroidal immunosuppressants was higher among patients with GC use than those without (37.6% any GC use vs 19.6% no GC use). Incident GC toxicities were higher in patients with any GC use than those without (61.9% vs 52.3%). Common acute toxicities included nausea and vomiting, pneumonia, fungal infections, sepsis, and urinary tract infection; chronic toxicities were dyslipidemia, sleep disturbances, obesity, cardiac arrhythmias, and hypertension. Annual all-cause costs were\u2005&gt;2x higher among patients with any GC use than those with no GC use ($76,381 vs $35,309). GC acute and chronic toxicities and costs tended to increase with increasing GC use. Since claims data do not contain reasons for diagnoses, toxicities could not be confirmed to be related to GC use. Additionally, results may be confounded by disease severity or concomitant medications. Effective GC-sparing treatments are needed to mitigate the clinical and economic burden of GC use in adults with gMG.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047979","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:00:48Z","timestamp":1774036848000},"page":"e47979","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Burden of glucocorticoid use in commercially insured adults with generalized myasthenia gravis in the United States: A retrospective claims-based analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Nicholas J.","family":"Silvestri","sequence":"first","affiliation":[{"name":"Department of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9099-0975","authenticated-orcid":false,"given":"Jenny Y.","family":"Park","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Serra","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gagnon-Sanschagrin","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[{"name":"Analysis Group ULC, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Canales","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina R.","family":"Patterson","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Meyers","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan","family":"Vu","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of South Florida, Tampa, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","article-title":"Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals.","volume":"82","author":"Menon","year":"2022","journal-title":"Drugs"},{"key":"R2-20260422","first-page":"e50017","article-title":"Myasthenia gravis: a systematic review.","volume":"15","author":"Mishra","year":"2023","journal-title":"Cureus"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"1339167","DOI":"10.3389\/fneur.2024.1339167","article-title":"Epidemiology of myasthenia gravis in the United States.","volume":"15","author":"Ye","year":"2024","journal-title":"Front Neurol"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis.","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20260422","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm11061597","article-title":"Current treatment of myasthenia gravis.","volume":"11","author":"Alhaidar","year":"2022","journal-title":"J Clin Med"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary.","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1038\/s41598-024-57825-1","article-title":"Patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations.","volume":"14","author":"Anderson","year":"2024","journal-title":"Sci Rep"},{"key":"R8-20260422","doi-asserted-by":"crossref","first-page":"e16180","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy.","volume":"31","author":"Sacca","year":"2024","journal-title":"Eur J Neurol"},{"key":"R9-20260422","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update.","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1080\/03007995.2024.2353381","article-title":"Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events.","volume":"40","author":"Zhdanava","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/acr2.11550","article-title":"Clinical and economic burden in patients with systemic lupus erythematosus during the first year after initiating oral corticosteroids: a retrospective US database study.","volume":"5","author":"DerSarkissian","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1177\/0961203318790675","article-title":"Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.","volume":"27","author":"Kabadi","year":"2018","journal-title":"Lupus"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40264-019-00867-6","article-title":"Adverse events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: an administrative claims analysis.","volume":"43","author":"Schultz","year":"2020","journal-title":"Drug Saf"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"809999","DOI":"10.3389\/fneur.2021.809999","article-title":"Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States.","volume":"12","author":"Phillips","year":"2021","journal-title":"Front Neurol"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3899\/jrheum.160214","article-title":"Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study.","volume":"45","author":"Chen","year":"2018","journal-title":"J Rheumatol"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"e933296","DOI":"10.12659\/MSM.933296","article-title":"Adverse side effects associated with corticosteroid therapy: a study in 39 patients with generalized myasthenia gravis.","volume":"27","author":"Johnson","year":"2021","journal-title":"Med Sci Monit"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"120531","DOI":"10.1016\/j.jns.2022.120531","article-title":"A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment.","volume":"445","author":"Ting","year":"2023","journal-title":"J Neurol Sci"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/1756-185X.13088","article-title":"Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial.","volume":"20","author":"Wu","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40744-025-00763-9","article-title":"Burden of glucocorticoid use and risk of toxicities among patients with immunoglobulin-G4-related disease: a retrospective US-based claims study.","volume":"12","author":"Wallace","year":"2025","journal-title":"Rheumatol Ther"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/mus.28328","article-title":"International consensus guidance for the management of glucocorticoid related complications in neuromuscular disease.","volume":"71","author":"Bacher","year":"2025","journal-title":"Muscle Nerve"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1212\/WNL.0000000000013121","article-title":"Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG Study.","volume":"98","author":"Nowak","year":"2022","journal-title":"Neurology"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa2501561","article-title":"A phase 3 trial of inebilizumab in generalized myasthenia gravis.","volume":"392","author":"Nowak","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:56:53Z","timestamp":1786035413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047979","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2025-11-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}